Please assess the completion status of the following clinical trial:

Trial Title: Argatroban in Critically Ill Patients With Heparin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient at risk for thrombosis or thromboembolic complications with the need of prophylactic antithrombotic therapy~* Age: 18 - 85 years~* Prohylactic anticoagulation (aPTT: 45 - 60 sec) is not achieved with a heparin dosage of 1.200 IU per hour after two hours of infusion~Exclusion Criteria:~* If patient needs an aPTT-level \> 60 sec for any reason~* Active bleeding~* Risk for bleeding higher than risk of thromboembolic event as anticipated by the physician~* Surgical procedure with the need for interruption of antithrombotic therapy within the next 24 hours~* Inevitable lethal course~* Severe Liver failure: Quick \< 30 %~* Pregnancy~* Planned peridural or spinal anaesthesia during the study~* Patient with known refusal of a participation in this clinical trial~* Active participation in another clinical trial~* Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study or confound the ability to interpret data from the study~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: NO_INTERVENTION): If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
- Treatment with Argatroban (Type: EXPERIMENTAL): If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).